GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Veraxa Biotech AG Ordinary Shares VRXA · USD

US listing · 🇺🇸 United States

Compare

1.01

+6.32%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Veraxa Biotech AG Ordinary Shares

Its shares trade under the ticker VRXA. It has been listed since 11 June 2026. In the fiscal year to 31 December 2025, it reported revenue of $28,783 and a net loss of $81.8m. At that date it held total assets of $99.3m and shareholders' equity of −$19.4m.

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
11 Jun 2026
Website
veraxa.com ↗
Head office
TALACKER 35, ZURICH, 8001
Incorporated in
V8
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment
  • Offers proprietary technology platform for functional antibody screening and bioconjugation
  • Utilizes proprietary payloads and genetic code expansion technology for homogeneous bioconjugates

Weaknesses

  • Sector and industry are unknown
  • IPO date is in the future (2026-06-11)
  • Company was founded in 2021, which may indicate limited operational history

Opportunities

  • Expanding product pipeline with ADCs and BITACs in clinical development
  • Providing partnership models for collaborative development from target identification
  • Licensing technology platforms to support new therapeutic strategies

Threats

  • Untrusted source description may contain inaccurate information
  • Company serves professional clients in healthcare sector with unknown sector and industry
  • Future IPO date may create uncertainty for investors

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.